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Introduction
TGFβs are cytokines with manifold key roles in modulating cell 
proliferation and differentiation, apoptosis, immune responses, 
tissue repair, and ECM formation (Massague, 1990; Border and 
Ruoslahti, 1992; Letterio and Roberts, 1998; Derynck et al., 
2001). TGFβ1, the fi  rst of 3 isoforms (TGFβ1–3) to be identi-
fi  ed, is the prototype of a superfamily of cytokines, related in 
domain structure and sequence homology, that is divisible into 
subfamilies based on degree of sequence homology (Ducy and 
Karsenty, 2000). The TGFβ1–3 subfamily is closely related to 
the activin subfamily and to growth and differentiation factors 
(GDFs) 8 (aka myostatin) and 11 (Ducy and Karsenty, 2000). 
All superfamily members act by binding cell surface type I and 
II receptor heterotetramers, with signal transduction to the nu-
cleus via Smad-dependent or -independent pathways (Massague 
et al., 2005).
Signaling by TGFβ-like ligands is tightly controlled by 
various intracellular, cell surface, and extracellular inhibitory 
proteins (Massague et al., 2005; Zacchigna et al., 2006). Signaling 
by TGFβ1–3 and GDF8 and -11 is also blocked by formation of 
a noncovalent latent complex between the functional ligand and 
its cleaved prodomain (Massague, 1990; Annes et al., 2003; 
Wolfman et al., 2003; Ge et al., 2005), designated latency-
  associated peptide (LAP) for TGFβ1–3 (Annes et al., 2003). 
TGFβ1–3 are produced as large latent complexes (LLCs) in 
which LAP is disulfi  de bonded to a latent TGFβ-binding protein 
(LTBP), of which mammals have four (Annes et al., 2003). It re-
mains unclear which processes activate TGFβ latent complexes 
in vivo, although cleavage within LAP sequences by plasmin 
and/or matrix metalloproteinases (MMPs; Lyons et al., 1988; 
Sato and Rifkin, 1989; Yu and Stamenkovic, 2000; D’Angelo 
et al., 2001; Maeda et al., 2001; Mu et al., 2002) and/or nonpro-
teolytic dissociation of LAP from active TGFβ, caused by inter-
actions with thrombospondin (Crawford et al., 1998) or integrin 
αVβ6 (Munger et al., 1999), may be involved. Although overall in 
vivo roles of LTBPs remain obscure, they serve to bind LLCs 
to ECM, perhaps via covalent linkage of LTBPs to ECM 
  com  ponents (Nunes et al., 1997). Ability of LTBP1 to fi  x LLC to 
ECM appears involved in its ability to promote αVβ6-mediated 
TGFβ activation, whereas the apparent ability of LTBPs to 
 facilitate  TGFβ activity in other situations is by as-yet-unclear 
mechanisms (Flaumenhaft et al., 1993; Nakajima et al., 1997; 
Gualandris et al., 2000).
Bone morphogenetic protein 1 (BMP1)–like proteinases 
affect morphogenesis by biosynthetic processing of precursors 
to mature functional proteins necessary to ECM formation. 
Such proteins include collagens I–III (Kessler et al., 1996), 
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ransforming growth factor β1 (TGFβ1), an impor-
tant regulator of cell behavior, is secreted as a large 
latent complex (LLC) in which it is bound to its 
cleaved prodomain (latency-associated peptide [LAP]) 
and, via LAP, to latent TGFβ-binding proteins (LTBPs). The 
latter target LLCs to the extracellular matrix (ECM). Bone 
morphogenetic protein 1 (BMP1)–like metalloproteinases 
play key roles in ECM formation, by converting precur-
sors into mature functional proteins, and in morphoge-
netic patterning, by cleaving the antagonist Chordin to 
activate BMP2/4. We provide in vitro and in vivo evi-
dence that BMP1 cleaves LTBP1 at two speciﬁ  c sites, thus 
liberating LLC from ECM and resulting in consequent acti-
vation of TGFβ1 via cleavage of LAP by non–BMP1-like 
proteinases. In mouse embryo ﬁ  broblasts, LAP cleavage 
is shown to be predominantly matrix metalloproteinase 
2 dependent. TGFβ1 is a potent inducer of ECM forma-
tion and of BMP1 expression. Thus, a role for BMP1-like 
proteinases in TGFβ1 activation completes a novel fast-
forward loop in vertebrate tissue remodeling.
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V, VII, and XI; proteoglycans biglycan and osteoglycin; base-
ment component laminin 5; and the cross-linking enzyme lysyl 
oxidase (Ge and Greenspan, 2006). BMP1-like proteinases also 
affect morphogenesis by activating BMP2 and -4 via cleaving 
the extracellular antagonist Chordin and thus regulating patte-
rning (Blader et al., 1997; Piccolo et al., 1997; Pappano et al., 
2003). In addition, BMP1-like proteinases activate GDF8 and 
-11 by cleaving within noncovalently bound prodomains to 
  release mature GDF8 and -11 from latent complexes (Wolfman 
et al., 2003; Ge et al., 2005), thus affecting negative growth 
  control of skeletal muscle and neural tissues, for which GDF8 
and -11, respectively, are responsible (McPherron et al., 1997; 
Wu et al., 2003).
Here, we use in vitro and in vivo approaches to demon-
strate that BMP1-like proteinases serve to activate TGFβ by 
  direct cleavage of LTBP1, resulting in liberation of LLCs from 
ECM and consequent MMP-dependent LAP cleavage. Because 
BMP1 is potently induced by TGFβ1 (Lee et al., 1997), its role 
in TGFβ1 activation completes a novel amplifi  cation loop in 
vertebrate tissue remodeling. Moreover, BMP1-like proteinases 
are identifi  ed as regulators capable of orchestrating TGFβ sig-
naling with ECM deposition, patterning, and negative feedback 
control of muscle and neural tissue growth.
Results
BMP1 cleaves LTBP1 but not LAP
To determine whether BMP1 might play a role in proteolytic 
activation of TGFβ1, BMP1 was incubated with TGFβ1 LLC. 
A Western blot probed with antibody to a C-terminal His tag 
demonstrated dose-dependent cleavage of an  17-kD fragment 
from the C-terminal portion of  190-kD LTBP1 (Fig. 1 A). 
A similar blot probed with anti-LTBP1 (Fig. 1 B) demonstrated 
a corresponding reduction in size of the remainder of LTBP1 to 
produce a doublet or, at higher BMP1 concentrations, a single 
band of  150 kD. N-terminal amino acid sequencing of the 
150- and 17-kD LTBP1 fragments demonstrated that cleavages 
had occurred at peptide bonds 
485L-D
486 and 
1285Q-D
1286, respec-
tively. The former of these sites occurs between the most 
N-  terminal 8-Cys motif and the second most N-terminal non-
Ca
2+ binding EGF-like domain, within the fl  exible hinge region 
of LTBP1 (Fig. 1 C). The latter cleavage occurs between the 
most C-terminal 8-Cys motif and the most C-terminal non-Ca
2+ 
binding EGF-like domain. Both sites have P1’ Asp residues 
and other features characteristic of cleavage sites of previously 
identifi  ed BMP1 substrates (Fig. 1 D). Control experiments 
showed both sites to be effi  ciently cleaved, with cleavage at the 
N- and C-terminal sites occurring within 10 and 30 min of incu-
bation with BMP1, respectively (Fig. S1, available at http://
www.jcb.org/cgi/content/full/jcb.200606058/DC1). Control 
  experiments also demonstrated that BMP1 must be catalytically 
active for LTBP1 cleavage to occur, as even prolonged incuba-
tion with catalytically inactive BMP1, in which the protease do-
main active site Glu
94 had been substituted for with Ala, did not 
alter LTBP1 electrophoretic mobility (Fig. S1).
In contrast to its ability to cleave LTBP1, active BMP1 did 
not cleave  37-kD LAP to a smaller size, nor did it cleave 
within the  50-kD precursor molecule consisting of LAP cova-
lently bound to the mature portion of TGFβ1 (Fig. 1 E). Under 
nonreducing conditions, an immunoblot analysis with anti-LAP 
antibodies showed  290-kD intact LLC to be cleaved to an 
 245-kD form by BMP1 (Fig. 1 F). Interestingly, mobility cor-
responding to 245 kD, rather than the 37 kD expected for disso-
ciated LAP, indicates that LAP remains associated with LTBP1 
subsequent to cleavage of the latter by BMP1 (Fig. 1 F).
BMP1-like proteinases are necessary 
for direct cleavage of LTBP1 and indirect 
cleavage of LAP by cells
To determine whether BMP1-like proteinases are used for in 
vivo LTBP1 cleavage, we compared processing of LTBP1 by 
wild-type mouse embryo fi  broblasts (MEFs) to processing of 
LTBP1 by MEFs derived from embryos doubly homozygous 
null for the Bmp1 gene, which encodes alternatively spliced 
Figure 1.  BMP1 cleaves LTBP-1, but not LAP, in vitro. TGFβ1 LLC was 
  incubated in the absence (−) or presence of low (25 ng) or high (250 ng) 
amounts of BMP1, and cleavage monitored by Western blots was probed 
with antibody to the C-terminal His tag of LTBP1 (A) or with anti-LTBP1 anti-
body (B). (C) A schematic is shown of LTBP1. H, hybrid domain; C1–3, 
8-cysteine domains 1–3. Green boxes indicate non-Ca
2+ binding EGF-like 
repeats, light orange boxes indicate Ca
2+ binding EGF-like repeats, and 
the scissors indicate BMP1 cleavage sites. LAP (blue) is shown disulﬁ  de 
bonded to the C2 domain, and active TGFβ (dark orange) is shown non-
covalently bound to LAP. (D) Alignment of LTBP1 cleavage sites with cleav-
age sites of known substrates of BMP1-like proteinases. Aspartates present 
at the P1’ sites of most cleavage sites of BMP1-like proteinases are in red, 
whereas other residues enriched near cleavage sites of known substrates 
of BMP1-like proteinases are in green. (E and F) TGFβ1 LLC was incubated 
in the absence (−) or presence (+) of BMP1, with samples analyzed by 
SDS-PAGE under reducing (E) or nonreducing (F) conditions, followed by 
Western blot analysis with anti-LAP antibodies. Numbers to the sides of 
blots correspond to the positions and approximate sizes in kD of molecular 
mass markers or known protein bands. In some cases, the molecular 
masses of known proteins are noted parenthetically next to the name of the 
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mRNAs for proteinases BMP1 and mammalian tolloid (Ge and 
Greenspan, 2006), and the Tll1 gene, which encodes the BMP1-
like proteinase mammalian tolloid–like 1 (Ge and Greenspan, 
2006). Simultaneous ablation of the functionally redundant pro-
ducts of Bmp1 and Tll1 has previously been shown to remove 
detectable processing activity for various substrates of BMP1-
like proteinases (Pappano et al., 2003). Cells produce short and 
long forms of LTBP1 (LTBP1S and -L, respectively), resulting 
from alternative splicing and multiple transcriptional promoters 
(Koski et al., 1999), and both LTBP1S and -L were found to dif-
fer in electrophoretic mobility in wild-type and Bmp1/Tll1 dou-
bly null MEF media samples (Fig. 2 A). Moreover, sizes of 
LTBP1S in wild-type (150 kD) and Bmp1/Tll1-null (190 kD) 
samples corresponded, respectively, to sizes of BMP1-cleaved 
and uncleaved recombinant LTPB1S (Fig. 1 B).
It has been reported that removal of sequences N-terminal 
to the hinge region is suffi  cient to release LTBP1 from transglu-
taminase-dependent covalent association with ECM (Taipale 
et al., 1994; Nunes et al., 1997). Because such sequences are 
N-terminal to the 
485L-D
486 BMP1 cleavage site demonstrated 
here, the decreased amounts of LTBP1S and -1L in Bmp1/Tll1-
null, compared with wild-type MEF medium (Fig. 2 A), is con-
sistent with the probability that cells use BMP1-like proteinases 
to process the LTBP1 hinge region and that this is suffi  cient to 
release TGFβ1 LLC from ECM. Buttressing this probability 
was the observation that markedly greater amounts of LTBP1 
fragments are released by plasmin from Bmp1/Tll1-null than 
from wild-type MEF ECM (Fig. 2 B).
Surprisingly, although BMP1 does not cleave LAP in  vitro 
(Fig. 1 E), the electrophoretic mobility of LAP was increased in 
wild-type compared with Bmp1/Tll1-null MEF media (Fig. 2 C). 
Because the mobility of LAP from Bmp1/Tll1-null MEF 
  media is equal to that of full-length LAP, these results are con-
sistent with the probability that LAP is cleaved in wild-type, but 
not Bmp1/Tll1-null, MEF cultures. To determine the type of 
proteinases responsible for LAP cleavage, wild-type MEFs 
were cultured in the presence of inhibitors of metallo- (TNF-α 
processing inhibitor 2 [TAPI-2]), cysteine- (E64), aspartic- 
(pepstatin A), and serine- (4-[2-aminoethyl]-benzenesulfonyl 
fl  uoride [AEBSF]) proteinases. Only TAPI-2, which inhibits 
metalloproteinase sheddases and a range of MMPs, inhibited 
LAP processing in MEF cultures, whereas none of the inhibitors 
interfered with LTBP1S or -L processing (Fig. 2 D). Importantly, 
BMP1 is not inhibited by even 200 μM TAPI-2 in vitro 
(unpublished data), consistent with the interpretation that LAP 
in wild-type MEF cultures is cleaved by metalloproteinases not 
of the BMP1 subgroup.
Tissue inhibitor of metalloproteinase 3 (TIMP-3) has in-
hibitory activity toward all MMPs and against some members of 
the ADAM (a disintegrin and metalloproteinase) family of pro-
teinases (Visse and Nagase, 2003) but has no inhibitory activity 
against BMP1 (Wang et al., 2006). When wild-type MEFs were 
cultured in the presence of the N-terminal inhibitory domain of 
TIMP-3, which has the same inhibitory activity as the full-length 
protein (Kashiwagi et al., 2001), processing of LAP but not 
LTBP1 was inhibited (Fig. 2 E), consistent with the conclusion 
that LAP is cleaved by non–BMP1-like metalloproteinases.
LAP cleavage is MMP2 dependent
MMP2, - 9, and -14 have previously been identifi  ed in vitro as 
  metalloproteinase activators of TGFβ (Sato and Rifkin, 1989; Yu 
and Stamenkovic, 2000; Mu et al., 2002). Thus, RNAi knockdown 
was performed in wild-type MEFs, to test whether any of these 
might play a role in cleaving LAP in LLCs released from ECM by 
BMP1. RNAi knock down of each MMP was effective at RNA 
(Fig. 3 A) and protein (Fig. 3 B) levels. Interestingly, MMP9 RNA 
and protein levels were also reduced upon knock down of MMP2.
Figure 2.  LLCs are not proteolytically processed in cultures of MEFs   doubly 
homozygous null for the Bmp1 and Tll1 genes. Western blot analysis with 
anti-LTPB1 antibodies was used to monitor proteolytic processing of LTBP1 
to LTBP1 cleavage products (cp) in conditioned media from 4-d cultures of 
wild-type or Bmp1/Tll1 doubly null MEFs (A) or monitor amounts of LTBP1 
released by plasmin from ECM of 2- or 4-d wild-type or Bmp1/Tll1 doubly 
null MEF cultures (B). (C) Western blot analysis with anti-LAP antibodies 
was used to monitor LAP proteolytic processing in conditioned media from 
4-d wild-type or Bmp1/Tll1 doubly null MEF cultures. (D) Western blot 
  analyses were used to monitor proteolytic processing of LAP and LTBP1 in 
  conditioned media of wild-type MEFs cultured in the presence of inhibitors 
of metallo- (TAPI-2), cysteine- (E64), aspartic- (pepstatin A), and serine- 
(AEBSF) proteinases. (E) Western blot analyses with anti-LAP and anti-LTBP1 
antibodies shows that the inhibitory N-terminal domain of TIMP-3 (N-TIMP-3) 
inhibits processing of LAP, but not LTBP1, in wild-type MEF cultures. Num-
bers to the left of blots correspond to the positions and approximate sizes 
in kD of molecular mass markers or known protein bands. In some cases, 
the molecular masses of known proteins are noted parenthetically next to 
the name of the protein.JCB • VOLUME 175 • NUMBER 1 • 2006  114 
Analysis of LAP from conditioned media showed that 
knock down of MMP2, but not of the other two MMPs, resulted 
in inhibition of LAP cleavage, such that electrophoretic mobility 
was the same as for LAP isolated from Bmp1/Tll1-null MEF 
  medium (Fig. 3 C). Consistent with the latter results, Smad2/3 
phosphorylation, a direct downstream indicator of TGFβ-specifi  c 
signaling (Massague et al., 2005), was much reduced in MMP2 
RNAi-treated MEFs, compared with untreated MEFs or MEFs 
treated with MMP9 or -14 RNAi (Fig. 3 D). Thus, MMP2 is nec-
essary for LAP cleavage and TGFβ activation in MEFs, subse-
quent to BMP1 liberation of LLC from ECM. MMP2-dependent 
TGFβ activation probably explains the decrease in MMP9 RNA/
protein levels upon MMP2 RNAi treatment, as MMP9 RNA/ 
protein levels are elevated by TGFβ activity (Sehgal and 
Thompson, 1999). In Fig. 3 E, it is demonstrated that MMP2 
is capable of in vitro cleavage of LAP in small latent complexes 
(SLC), yielding a fragment similar in size to the LAP fragment 
in wild-type MEF media (Figs. 2, C and D; Fig. 3 C). In contrast, 
MMP2 cleavage of LLC-associated LAP was extremely ineffi  -
cient, without prior incubation of LLC with BMP1 (Fig. 3 F). 
Thus, in vitro, as in vivo, prior LLC processing by BMP1 greatly 
facilitates subsequent MMP2 cleavage of LAP. Under nonreduc-
ing conditions, immunoblot analysis with anti-LAP antibodies 
showed LLC to be cleaved to an  230-kD form upon incubation 
with BMP1 and MMP2 (Fig. 3 G). Mobility corresponding to a 
230-kD form, rather than the 35 kD expected for cleaved and 
dissociated LAP, indicates that LAP remains associated with 
LTBP1 subsequent to BMP1 cleavage of LTBP1 and MMP2 
cleavage of LAP.
It should be noted that the aforementioned studies do not 
formally rule out roles for MMP9 and -14 in TGFβ activation 
in MEFs, as RNAi knock down of MMP2 also resulted in a 
knock down of MMP9 protein that was more dramatic than 
that achieved with MMP9 RNAi (Fig. 3 B), whereas levels of 
MMP14 protein could not be ascertained in knockdowns 
  because of the unavailability of antibodies capable of detecting 
murine MMP14 via immunoblotting. Indeed, the role of 
MMP14 in activating MMP2 (Visse and Nagase, 2003)  ensures 
some level of contribution of MMP14 to TGFβ activation 
in MEFs.
Cell cultures and tissues have increased 
levels of LTBP1 deposition and 
reduced TGF𝗃 activity in the absence 
of BMP1-like proteinases
It has previously been shown that LTBP1-containing LLCs can 
be deposited in ECM as extracellular fi  brillar structures associ-
ated with fi  brillin microfi  brils (Dallas et al., 2000; Isogai et al., 
2003). To determine whether ablation of Bmp1 and Tll1 affects 
the appearance of LTBP1 in ECM, anti-LTBP1 immunofl  uores-
cence was performed for comparison of wild-type and Bmp1/
Tll1-null MEF cell layers. Consistent with the results of Fig. 
2 B, in which levels of ECM-associated LTBP1 were markedly 
increased in Bmp1/Tll1-null MEF cell layers compared with 
wild type, detectable fi  brillar structures containing LTBP1 were 
greatly increased in number and thickness in Bmp1/Tll1-null 
MEF cell layers compared with wild type (Fig. 4 A). In contrast, 
fi  brillin 1 microfi  brils were similar in numbers and thickness in 
mutant and wild-type cell layers.
Cleavage of LAP in wild-type but not Bmp1/Tll1-null 
MEF cultures suggested that TGFβ activity might be reduced in 
the latter. To test this, levels of active TGFβ in wild-type and 
Bmp1/Tll1-null MEF cultures were compared by adding condi-
tioned media to a reporter gene assay consisting of mink lung 
epithelial cells stably transfected with a luciferase gene driven 
by TGFβ-responsive plasminogen activator inhibitor 1 pro-
moter sequences (T-MLEC [transfected mink lung epithelial 
cell]). Assay results clearly demonstrated Bmp1/Tll1-null MEF 
media to have lower TGFβ activity levels than wild type (Fig. 4 B), 
even though the two types of media had similar levels of TGFβ 
protein, as demonstrated by the similar levels of activity 
obtained upon heat activation (Fig. 4 C). Thus, although the two 
types of MEF culture media have similar levels of TGFβ, much 
more is in a latent form in Bmp1/Tll1-null than in wild-type 
 medium. In a control experiment, the use of either of two different 
TGFβ-neutralizing antibodies (one specifi  c for TGFβ1 and the 
other a pan-specifi  c TGFβ antibody that reacts with TGFβ1–5) 
was capable of reducing both wild- type and Bmp1/Tll1-null 
MEF media activity levels in the T-MLEC reporter gene assay 
to baseline levels (Fig. 4 D), thereby demonstrating such activity 
to be due predominantly to TGFβ1, rather than to other factors 
that act through the Smad2/3 signaling pathway. In another 
Figure 3.  LAP cleavage is MMP2 dependent. (A) Levels of MMP2, MMP9, 
MMP14, or GAPDH RNA were compared by RT-PCR. Sizes of cDNA 
bands in bp are noted in brackets to the right of the panel. Western blot 
analysis using anti-proMMP2, anti-MMP9, or anti-PCOLCE1 antibodies 
(B) or anti–phospho-Smad2/3 or anti-tubulin antibodies (D) was performed 
on samples from wild-type MEFs subjected to RNAi knock down of MMP2, 
-9, or -14, or using a scrambled RNAi duplex control. (C) Western blot 
analysis with anti-LAP or anti-LTBP1 antibodies was performed on samples 
from Bmp1/Tll1 doubly null MEFs or from wild-type MEFs subjected to 
RNAi knock down of MMP2, -9, or -14, or using a scrambled RNAi duplex 
control. Western blot analysis with anti-LAP antibodies was performed 
on SLC (E) or on LLC (F and G) incubated with (+) or without (−) MMP2. 
In F and G, MMP2 cleavage was subsequent to incubation in the presence 
(+) or absence (−) of BMP1. The numbers beneath lanes indicate signal 
intensity relative to signal in control lane (B and D). The numbers to the left 
of blots correspond to the positions and approximate sizes in kD of molecular 
mass markers or known protein bands. In some cases, the molecular 
masses of known proteins are noted parenthetically next to the name of 
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  control experiment, to ensure that latent TGFβ complexes in 
harvested wild-type and Bmp1/Tll1-null MEF conditioned 
  media were not differentially activated during in vitro handling 
before addition to T-MLEC cultures; MEFs were cocultured 
with T-MLECs, directly followed by harvesting of monolayers 
and determination of amounts of luciferase activity. As shown 
in Fig. 4 E, coculturing confi  rmed wild-type MEFs to have in-
trinsically higher levels of TGFβ signaling than Bmp1/Tll1-null 
MEFs. We have found T-MLECs to secrete active BMP1 
  (unpublished data), which may release some LLC from ECM 
during coculturing, thus accounting for the somewhat smaller 
difference in TGFβ activity levels between wild-type and Bmp1/
Tll1-null MEFs in the coculturing experiment (Fig. 4 E), com-
pared with differences found in experiments in which conditioned 
  media were added to T-MLEC cultures (Figs. 4, B and D).
We next assayed for evidence of effects of decreased TGFβ 
activity on Bmp1/Tll1-null MEF cells. It has been reported that 
TGFβ1 induces increased levels of MMP2 and -9 via transcrip-
tional, posttranscriptional, and posttranslational mechanisms 
(Brown et al., 1990; Overall et al., 1991; Marti et al., 1994;   Sehgal 
and Thompson, 1999). Thus, we compared MMP2 and -9 levels in 
Bmp1/Tll1-null and wild-type MEF conditioned media. Results 
showed levels of MMP2 RNA (Fig. 4 F) and protein (Fig. 4 G) to 
be markedly higher in wild-type than in Bmp1/Tll1-null MEF cul-
tures and showed differences in MMP9 RNA and protein levels to 
be even more pronounced. Similarly, levels of CYR61, an estab-
lished marker for TGFβ activity (Brunner et al., 1991), were mark-
edly higher in wild-type than in Bmp1/Tll1-null MEF cultures. In 
contrast, levels of the protein PCOLCE1, expression of which has 
been shown not to be affected by TGFβ1 (Lee et al., 1997), were 
similar in Bmp1/Tll1-null and wild-type MEF media (Fig. 4 G). 
Next, levels of phosphorylated/activated Smad2/3 were compared 
in Bmp1/Tll1-null and wild-type MEFs. As shown in Fig. 4 H, 
phosphorylated Smad2/3, readily detectable in wild-type MEFs, 
was diffi  cult to detect in Bmp1/Tll1-null MEFs under the same 
conditions. Thus, Bmp1/Tll1-null MEFs bear multiple hallmarks 
of cells with reduced levels of TGFβ signaling.
We next assayed for differences in levels of detectable 
LTBP1 and levels of TGFβ signaling in tissues of 13.5-d post 
conception (dpc) wild-type and Bmp1/Tll1-null embryos. As pre-
viously reported (Isogai et al., 2003), labeling of wild-type tissues 
with anti–LTBP-1 was sparse. However, markedly higher levels 
of LTBP1 fi  brillar networks were detected in Bmp1/Tll1-null tis-
sues (Fig. 5 A). In contrast, wild-type tissues had markedly higher 
levels of phosphorylated Smad2/3 than did Bmp1/Tll1-null tis-
sues, consistent with markedly higher levels of TGFβ signaling 
(Fig. 5 A). In contrast to both these results, levels and distribu-
tions of fi  brillin 1 microfi  brils were similar in the two types of 
  tissues. That the overabundant LTBP1 in Bmp1/Tll1-null tissues, 
which predominantly colocalizes with fi  brillin fi  brils (unpublished 
data), does not alter the appearance of   fi  brillin fi  brils compared 
with wild type is consistent with previous biochemical evidence 
Figure 4.  Comparison of ﬁ  brillar LTBP1 deposition, TGF𝗃 
activity, and MMP levels in Bmp1/Tll1 doubly null and wild-
type MEF cultures. (A) Wild-type (WT) and Bmp1/Tll1 dou-
bly null MEF cell layers were subjected to immunoﬂ  uorescence 
staining, using polyclonal anti-LTBP1 or anti–ﬁ  brillin 1 (FBN1) 
antibodies. Images were deconvoluted and contrast was ad-
justed with the same parameters.   Photomicrograph exposure 
times were identical per given antibody (1/8 and 1/15 s for 
anti-LTBP1 and anti–ﬁ  brillin 1, respectively) to ensure compa-
rability of signal levels for wild-type and mutant tissues. Bar, 
20 μm. (B–D) Bmp1/Tll1 doubly null MEF culture media 
contain similar levels of TGFβ but markedly lower levels of 
active TGFβ than wild-type culture media. Conditioned me-
dia from Bmp1/Tll1 doubly null and wild-type MEFs were 
separately added to a reporter gene assay without (B) or 
with (C) heat activation, for detection of active or total TGFβ, 
respectively. Aliquots of 2.5, 5, 10, 20, and 50 μl were 
added, as indicated. (D) In a control experiment, condi-
tioned media from Bmp1/Tll1 doubly null and wild-type 
MEFs were incubated 1 h at 4°C in the absence (−) or pres-
ence of either anti-TGFβ1 (αTGFβ1) or pan-speciﬁ  c (α pan 
TGFβ) anti-TGFβ antibody before addition to the reporter 
gene assay. (E) MEFs were cocultured with T-MLEC reporter 
cells, followed by scraping of cell layers for determination of 
luciferase levels. (B–E) Numbers on the ordinate axis repre-
sent fold increases in levels of luciferase activity. (F–H) Levels 
of TGFβ-induced MMPs and CYR61 are notably higher in 
wild-type than in Bmp1/Tll1 doubly null MEF cultures. (F) 25, 
30, and 35 cycles of RT-PCR were performed on RNA from 
wild-type and Bmp1/Tll1 doubly null MEFs. Sizes of cDNA 
bands in bp are noted in brackets to the right of the panel. 
(G and H) Western blot analyses were performed on media 
(G) and cell layers (H) of wild-type or Bmp1/Tll1 doubly 
null MEFs using antibodies to MMP2 (Chemicon), MMP9 
(Abcam), CYR61 (Santa Cruz Biotechnology, Inc.), and 
p-Smad2/3, and against PCOLCE1 (G; Lee et al., 1997) 
and tubulin (H; Oncogene) as loading controls. Molecular 
masses of known proteins are noted parenthetically next to 
the name of the protein.JCB • VOLUME 175 • NUMBER 1 • 2006  116 
that LTBP1 is a microfi  bril-associated protein, rather than an inte-
gral structural component of micro  fi  brils (Isogai et al., 2003).
Interestingly, it has previously been shown that impair-
ment of TGFβ signaling (Sasaki et al., 2006) and ablation of the 
Bmp1 gene (Suzuki et al., 1996) both result in retardation in for-
mation of the intramembranous frontal bone of the skull. Bmp1/
Tll1 doubly homozygous null embryos die at 13.5 dpc (Pappano 
et al., 2003), before formation of the frontal bone. Thus, we 
  assayed for possible differences in LTBP1 accumulation and 
TGFβ signaling in frontal bones of 17.5-dpc Bmp1
−/−/Tll1
+/− 
and wild-type embryos. As previously   reported for Bmp1
−/− 
17.5-dpc embryos (Suzuki et al., 1996), the gap between ossifi  ed 
portions of the forming frontal bones is greatly increased in 
Bmp1
−/−/Tll1
+/− compared with wild-type 17.5-dpc embryos 
(Fig. 5 B). Immunofl  uorescent staining showed fi  brillar struc-
tures containing LTBP1 to be greatly increased in number and 
thickness in Bmp1
−/−/Tll1
+/− compared with wild-type frontal 
bone, with localization predominantly to the periosteum lining 
the ossifi  ed bone and nonossifi  ed mesenchyme of the frontal 
bone primordium (Fig. 5 B). In contrast, markedly higher levels 
of signal for phosphorylated Smad2/3 were found in wild-type 
presumptive frontal bone and adjoining tissues than in corre-
sponding Bmp1
−/−/Tll1
+/− tissues. Levels of fi  brillin 1 microfi  -
brils were similar in wild-type and mutant tissues.
Discussion
Much of the TGFβ in tissues is in the form of LLCs linked to 
ECM via LTBPs. As such, they constitute a reservoir of key 
  cytokines that can be rapidly mobilized in response to tissue 
  perturbations. Interestingly, identifi  ed activators of TGFβ may 
all represent readouts of ECM perturbation (Annes et al., 2003). 
For example, MMP2 and -9 and plasmin play central roles in 
ECM degradation, whereas thrombospondin-1 expression is in-
duced in response to tissue damage and is involved in the early 
stages of ECM regeneration (Bornstein et al., 2004). Thus, in 
many cases, ECM perturbation may be an important signal caus-
ally preceding activation of TGFβ in ECM-bound LLCs. Indeed, 
ablation of fi  brillin1, the protein via which LTBP1 binds LLCs 
to ECM, is suffi  cient to yield raised TGFβ activity in tissues 
(Neptune et al., 2003); similarly, overexpression of truncated 
LTBP1 that is capable of binding SLC but incapable of binding 
ECM also yields raised TGFβ activity (Mazzieri et al., 2005). 
Both results support the concept that activation of LLC-associated 
TGFβ is greatly enhanced by, and may depend on, prior release 
from ECM.
Here, we describe a novel mechanism for TGFβ activation, 
involving LLC liberation from ECM via specifi  c LTBP1 cleav-
age by BMP1-like proteinases. This cleavage does not free LAP 
from LTBP1, nor does it free active TGFβ from LAP. Rather, the 
effect of this cleavage in both cell cultures and tissues appears to 
be consequent cleavage of LAP and activation of TGFβ by non–
BMP1-like metalloproteinases. In MEF cultures, we have dem-
onstrated this consequent cleavage to be dependent on MMP2 
and perhaps on other non–BMP1-like metalloproteinases as well 
and have demonstrated that prior BMP1 cleavage of LLC in vitro 
results in greatly enhanced susceptibility of LLC LAP to cleav-
age by MMP2. In other cell types, additional proteases may be 
Figure 5.  Increased LTBP1 accumulation and 
decreased TGF𝗃 signaling are found in Bmp1/
Tll1 doubly null tissues and accompany devel-
opmental failure of the frontal bone in 
Bmp1
−/−/Tll1
+/− embryos. (A)  Bmp1/Tll1 
doubly null tissues show decreased TGFβ sig-
naling and increased LTBP1 accumulation com-
pared with wild type (WT). Serial parasagittal 
sections of tissues of 13.5-dpc wild-type and 
Bmp1/Tll1 doubly null embryos were sub-
jected to hematoxylin/eosin (H&E) staining 
(top) and immunoﬂ   uorescent staining with 
polyclonal antibodies to LTBP1, phosphory-
lated Smad2/3, and ﬁ  brillin 1 (FBN1). Shown 
are cross sections of presumptive rib. (B) In-
creased LTBP1 accumulation and decreased 
TGFβ signaling accompany developmental 
failure of the frontal bone in Bmp1
−/−/Tll1
+/− 
embryos. Serial coronal sections of 17.5-dpc 
wild-type and Bmp1
−/−/Tll1
+/− embryos were 
subjected to hematoxylin/eosin staining (top) 
or immunoﬂ   uorescent staining. Arrowheads 
mark the boundaries of ossiﬁ  ed and nonossi-
ﬁ   ed mesenchymal portions of presumptive 
frontal bones. Insets in the top panels of B cor-
respond to the hematoxylin/eosin-stained sec-
tions immediately below. Note that although 
both margins of ossiﬁ  ed frontal bone are visi-
ble near the midline in wild type (B), only a 
single  Bmp1
−/−/Tll1
+/− margin is shown 
  because of the wide gap separating the two 
margins in retarded mutant frontal bone. For 
immunoﬂ   uorescence, photomicrograph expo-
sure times were identical per given antibody (1/8, 1/4, and 1/30 s for anti-LTBP1, anti–p-Smad2/3, and anti-FBN1, respectively) to ensure comparability 
of signal levels for wild-type and mutant tissues. Bars: (B, top) 80 μm; (A and B) 20 μm.BMP1 ACTIVATES TGF𝗃1 • GE AND GREENSPAN 117
involved in LAP cleavage, subsequent to BMP1 liberation of 
LLCs from ECM.
TGFβ potently induces net ECM formation by effecting 
decreased production of some ECM-degrading proteases and 
increased production of (1) endogenous inhibitors for such pro-
teases, (2) ECM structural proteins, (3) enzymes that stabilize 
ECM via cross-link formation (i.e., lysyl oxidase; Massague, 
1990), and (4) metalloproteinases necessary for biosynthetic 
processing of ECM structural proteins and lysyl oxidase to their 
mature functional forms (e.g., the BMP1-like proteinases; Lee 
et al., 1997; Wang et al., 2003). Thus, demonstration here that 
BMP1-like proteinases effect activation of TGFβ completes 
a novel feed-forward loop for net ECM deposition. This loop, 
illustrated in Fig. 6, is likely to feature in various morphogenetic 
events in which both BMP1-like proteinases and TGFβ and 
have been implicated as key players, including development, 
wound repair, angiogenesis (St Croix et al., 2000; Bertolino et al., 
2005), and synaptic plasticity (Zhang et al., 1997). Data pre-
sented herein are consistent with the possibility that this loop is 
necessary, in a nonredundant way, for normal formation of the 
frontal bone of the skull.
MMP2 and -9 and various other MMPs are capable of 
playing key roles in the tissue remodeling associated with 
the growth, angiogenesis, and invasiveness of tumors (Yu and 
Stamenkovic, 2000; Sternlicht and Werb, 2001). The same is 
true for TGFβ (Yu and Stamenkovic, 2000; Derynck et al., 
2001), whereas high throughput screens have identifi  ed BMP1 
RNA sequences as among the most up-regulated in activated 
endothelia associated with tumor angiogenesis (St Croix et al., 
2000). Thus, the fast-forward loop involving activation of TGFβ 
by TGFβ-inducible BMP1, with subsequent roles played by 
MMPs (Fig. 6), is of potential importance to the tissue remodel-
ing   associated with morphogenesis and to the pathogenesis of 
  cancers as well.
Clearly, mammals possess a variety of molecular mecha-
nisms for activating latent TGFβ, each of which may be suitable 
to a limited set of circumstances (Annes et al., 2003). Thus, 
BMP1 activation of TGFβ may be limited to some subset of cell 
types, to responses to only certain stimuli, and/or to the etiology 
of only some pathologies involving TGFβ activity. The range of 
cells and situations in which BMP1 participates in TGFβ acti-
vation in vivo remains to be determined.
Finally, BMP1-like proteinases are also responsible for 
activating BMP2 and -4 via cleavage of Chordin (Pappano et al., 
2003) and GDF8 and -11 via cleavage of prodomain sequences 
(Wolfman et al., 2003; Ge et al., 2005). Thus, they may serve to 
orchestrate signaling by these different morphogenetic TGFβ 
superfamily ligands and perhaps contribute to coordination 
 between R-Smad2/3 and R-Smad1/5/8 signaling pathways, used 
by TGFβ/GDF8/GDF11 and BMP2/4, respectively (Massague 
et al., 2005). They may even contribute to antagonism between 
the two pathways if, as in the case of Smad4 (Candia et al., 
1997), these proteinases occur in limiting amounts. Importantly, 
the previously characterized roles of the BMP1-like proteinases 
in ECM formation (Ge and Greenspan, 2006) and their newly 
identifi  ed roles as activators of TGFβ, make these proteinases 
potential targets for anti-fi  brotic therapeutic interventions.
Materials and methods
Production of recombinant proteins
Human LTBP1S sequences were PCR ampliﬁ  ed from placenta cDNA in two 
fragments. Primers were as follows: fragment 1 (amino acids 22–637), 
5′-G  A  T  C  G  C  T  A  G  C  A  C  A  C  A  C  T  G  G  C  C  G  C  A  T  C  A  A  G  G  T  -3′ (forward) and 
5′-C  G  T  C  C  G  G  C  C  T  C  A  G  G  C  A  T  T  -3′ (reverse); and fragment 2 (amino acids 
637–1396), 5′-C  G  A  A  T  G  C  C  T  G  A  G  G  C  C  G  G  A  -3′ (forward) and 5′-G  A  T  C-
G  C  G  G  C  C  G  C  T  A  A  T  G  G  T  G  A  T  G  G  T  G  A  T  G  A  T  G  C  T  C  C  A  G  G  T  C  A  C  T  G  T  C  T  T  T  C  T-
C  T  -3′ (reverse). Amplicons were joined at a shared Bsu36I site and joined 
via an NheI site to BM40 signal peptide sequences. The insert was placed 
between HindIII and NotI sites of tetracycline-inducible vector pcDNA4/
TO (Invitrogen). The resulting construct (pcDNA4/LTBP1S) expresses 
C-terminal His-tagged LTBP1S with BM40 signal peptide sequences for 
optimization of secretion. Human TGFβ1 sequences were PCR ampliﬁ  ed 
from placenta cDNA using primers 5′-G  A  T  C  G  C  T  A  G  C  A  G  A  C  T  A  C  A  A  A  G-
A  C    G    A  T  G  A  C  G  A  C  A  A  G  C  T  A  T  C  C  A  C  C  T  G  C  A  A  G  A  C  T  A  T  C  -3′ (forward) and 
5′-G  A  T  C  G  C  G  G  C  C  G  C  T  T  A  G  C  T  G  C  A  C  T  T  G  C  A  G  G  A  G  C  G  C  A  -3′ (reverse). 
Figure 6.  Manifold roles for BMP1-like 
  proteinases and the BMP1/TGF𝗃 feed-  forward 
loop for tissue remodeling. BMP1-like protein-
ases biosynthetically process ECM precursors 
(e.g., procollagen) to mature functional ECM 
components. They also activate TGFβ by pro-
cessing LTBP1 to release truncated LLC from 
ECM, leading to consequent activation via LAP 
cleavage by metalloproteinases such as MMP2. 
Activated TGFβ induces activation of R-Smad2 
and -3, which combine with Smad4 for translo-
cation to the nucleus and up-regulation (vertical 
  arrows) of BMP1, ECM precursors (e.g., procol-
lagen), MMP2, and TGFβ itself. TGFβ also 
down-regulates some MMPs that degrade ECM 
(e.g., MMP1). BMP1-like proteinases also acti-
vate BMP2/4 by cleaving the antagonist Chor-
din, thus inducing activation of R-Smad1, -5, and 
-8. The latter may compete with R-Smad2 and -3 
for limiting amounts of Smad4. Conceivably, 
Chordin competes with ECM precursors and 
LTBP1 for BMP1-like proteinases. Thus, Smad4 
and BMP1-like proteinases may represent two 
levels at which cross talk between TGFβ and 
BMP signaling pathways orchestrates tissue re-
modeling with patterning.JCB • VOLUME 175 • NUMBER 1 • 2006  118 
The amplicon, joined at an NheI site to BM40 signal peptide sequences, 
was subcloned between HindIII and NotI sites of tetracycline-inducible 
  vector pcDNA5/TO (Invitrogen). The resulting construct (pcDNA5/TGFβ1) 
expresses TGFβ1 in which the native signal peptide is replaced by the 
BM40 signal peptide and, upon cleavage of the signal peptide, a FLAG 
epitope remains at the LAP N terminus.
293 T-REx cells (Invitrogen) were maintained in DME, 5 μg/ml 
  blasticidin, and 10% FBS. 80% conﬂ   uent cells were cotransfected with 
pcDNA4/LTBP-1S and pcDNA5/TGFβ1, using Lipofectamine (Invitrogen). 
After 48 h, cells were selected in the same type of medium containing 
200 μg/ml Zeocin and 250 μg/ml hygromycin B. Ring-cloned colonies 
producing the highest tetracycline-induced levels of secreted LTBP1S and 
TGFβ1 were used for LLC production.
Conﬂ   uent cells were washed twice with PBS and incubated for 
15 min in serum-free DME at 37°C. Cells were then washed once with PBS 
and placed in serum-free DME/1 μg/ml tetracycline/40 μg/ml soybean 
trypsin inhibitor. Conditioned medium was harvested every 24 h, and 
  protease inhibitors were added to ﬁ  nal concentrations of 1 mM phenyl-
methylsulfonyl ﬂ  uoride, 1 mM N-ethylmaleimide, and 1 mM p-aminobenzonic 
acid. Conditioned medium was centrifuged to remove debris, and LLC was 
puriﬁ  ed by sequential afﬁ  nity puriﬁ  cation on Ni-NTA (QIAGEN) and anti-
FLAG M2 matrix (Sigma-Aldrich).
In vitro cleavage assays
500 ng LLC was incubated for 3 h alone or with 25 or 250 ng Flag-tagged 
BMP1 in 20 μl 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 10 mM 
CaCl2 at 37°C. An additional 25 or 250 ng BMP1 was then added and 
the reaction continued another 3 h. Reactions were stopped with 2× SDS 
sample buffer/1% β-mercaptoethanol and boiling for 5 min. For MMP2 
cleavage, 50 ng SLC or 150 ng LLC preincubated with/without BMP1 was 
incubated 16 h with/without 60 ng p-aminophenylmercuric acetate–acti-
vated proMMP2 (R&D Systems) in 20 μl 50 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, and 10 mM CaCl2 at 37°C. Reactions were stopped with 2× SDS 
sample buffer/1% β-mercaptoethanol and boiling for 5 min.
Amino acid sequence analysis
2 μg puriﬁ   ed recombinant LLC were cleaved as above. Products were 
  resolved on a 12% polyacrylamide SDS-PAGE gel, electrotransferred to 
Sequi-Blot polyvinylidene diﬂ  uoride membrane (Bio-Rad Laboratories), and 
stained with 0.025% Coomassie brilliant blue R-250. N-terminal amino 
acid sequencing was done by Edman degradation at the Harvard Micro-
chemistry Facility.
MEFs
Conﬂ   uent MEFs, isolated from 13.5-dpc embryos and immortalized as 
  described previously (Steiglitz et al., 2004), were washed twice with PBS, 
incubated in serum-free DME for 15 min at 37°C, and incubated for 24 h 
in serum-free DME and 40 μg/ml soybean trypsin inhibitor. Conditioned 
media were harvested, and protease inhibitors were added to ﬁ  nal 
  concentrations of 5 mM EDTA, 1 mM phenylmethylsulfonyl ﬂ  uoride, 1 mM 
N-ethylmaleimide, and 1 mM p-aminobenzonic acid for media used for 
Western blots. Inhibitors were not added to media for reporter gene   assays. 
All media were centrifuged to remove debris. For inhibition proﬁ  les, 80% 
conﬂ   uent wild-type or Bmp1/Tll1 doubly null MEFs were cultured 
24 h in DME/10% FBS with/without 20 μM E-64, 20 μM pepstatin A, 
100 μM AEBSF (Sigma-Aldrich), or 200 μM TAPI-2 (BIOMOL Research 
Laboratories, Inc.). Cells were then switched to inhibitor-containing serum-
free DME, and conditioned media were harvested 24 h later. For TIMP-3 
inhibition, 90% conﬂ  uent wild-type MEFs were cultured for 24 h in serum-
free DME with/without 100 ng/ml recombinant N-terminal inhibitor 
  domain of TIMP-3, which has inhibitory activity comparable to that of 
full-length TIMP-3 (Kashiwagi et al., 2001). Plasmin extraction of cell-
  associated ECM was as described previously (Koli et al., 2005).
Reporter gene assay
1.6 × 10
4 T-MLECs, stably transfected with a luciferase gene driven by 
TGFβ-responsive plasminogen activator inhibitor-1 promoter sequences 
(Abe et al., 1994; a gift from D. Rifkin, New York University, New York, 
NY), were allowed to attach for 3 h in 96-well plates. MEF conditioned 
medium (for active TGFβ estimation) or heat-treated conditioned medium 
(for total TGFβ estimation) were harvested and immediately (without 
  storage) added to the T-MLECs, which were harvested 24 h later. Coculture 
  experiments were performed as previously described (Jenkins et al., 2006). 
4 × 10
4 wild-type or Bmp1/Tll1 doubly null MEFs were cultured for 16 h 
in DME/10% FBS in 96-well plates to allow adhesion and cell spreading. 
1.6 × 10
4 T-MLECs were then added and allowed to attach for 3 h. Cells 
were then switched to serum-free medium containing 0.1% BSA. After 16 h, 
TGFβ activity was assessed by measuring luciferase activity in coculture 
cell layer lysates. Luciferase activity was measured using the Luciferase 
  assay system (Promega).
Immunohistochemistry and immunocytochemistry
13.5-dpc embryos were harvested, embedded in OCT (Tissue-Tek), frozen, 
and cut at −30°C into 10-μm sections. Frozen sections were thawed, ﬁ  xed 
for 20 min at 4°C with 2% paraformaldehyde in PBS, and washed for 
15 min at 4°C with PBS. Fixed cryosections were blocked for 4 h with 10% 
goat serum in PBS at room temperature and incubated overnight at 4°C 
with primary antibodies diluted in blocking solution. Rabbit polyclonal 
anti–phospho-Smad2/3 (Santa Cruz Biotechnology, Inc.), Ab39 anti-LTBP1 
(Kanzaki et al., 1990; a gift from C.-H. Heldin, Ludwig Institute for Cancer 
Research, Uppsala, Sweden), and 9543 anti–ﬁ   brillin 1 (Isogai et al., 
2003; a gift from L. Sakai, Shriners Hospital for Children, Portland, OR) 
primary antibodies were diluted 1:1,000. Sections were washed with PBS 
and incubated for 1 h at room temperature with Alexa Fluor 555 goat 
anti–rabbit secondary antibodies diluted in blocking solution. After wash-
ing with PBS, sections were mounted in Immu-Mount (Thermo Electron 
  Corporation), and viewed with a microscope (Axiophot 2; Carl Zeiss 
  MicroImaging, Inc.) with a Plan-NEOFLUAR 40× objective/0.75 aperture. 
Images were captured with a digital camera (ZVS-3C75DE; Carl Zeiss 
  MicroImaging, Inc.) and Digital Acquire software (DEI 750; Optronics).
4.5 × 10
4 MEFs were cultured 2 d in Lab-Tek chambers, washed 
once with PBS, ﬁ  xed for 10 min with methanol at –20°C, rinsed with PBS, 
blocked for 4 h with 3% BSA/PBS at room temperature, and incubated 
overnight at 4°C with primary antibodies diluted in blocking solution. Cells 
were washed with PBS, incubated for 1 h at room temperature with Alexa 
Fluor 555 goat anti–rabbit secondary antibody diluted in blocking solu-
tion, washed with PBS, and mounted in Immu-Mount. Images were decon-
voluted using AutoDeblur and AutoVisualize version 9.3 (AutoQuant 
Imaging, Inc.), and contrast was adjusted using Photoshop version 7.0 
(Adobe) with the same parameters.
RNAi
5 × 10
5 wild-type MEFs/well on a 6-well plate were transfected with 250 pmol 
Stealth RNAi duplexes for MMP2 (sense, 5′-U  A  U  U  C  C  C  G  A  C  C  G  U  U  G  A  A  C-
A  G  G  A  A  G  G  -3′), MMP9 (sense, 5′-U  A  U  A  C  A  G  C  G  G  G  U  A  C  A  U  G  A  G  C  G  C  U-
U  C  -3′), MMP14 (sense, 5′-A  A  A  C  U  U  A  U  C  C  G  G  A  A  C  A  C  C  A  C  A  G  C  G  A  -3′), 
or Stealth medium GC RNAi negative control (Invitrogen), using Lipo-
fectamine. After 6 h, cells were placed in DME/10% FBS, and 18 h later, 
they were changed into serum-free medium. Conditioned media were 
harvested after 24 h, as above. Cell layers were washed twice with ice-
cold PBS and scraped into hot SDS sample buffer for Western blotting. 
For RT-PCR, RNA was isolated with TRIzol (Invitrogen), and cDNA was 
synthesized using 1 μg RNA, random primers, and Super-Script II reverse 
transcriptase (Invitrogen). PCR was performed at 95°C/3 min, followed 
by 25, 30, or 35 cycles of 95°C/1 min, 60°C/1 min, and 72°C/1 min, 
and ﬁ   nal extension at 72°C/10 min. Primers were as follows: MMP2, 
5′-A  C  C  C  A  T  T  T  G  A  T  G  G  C  A  A  G  G  A  T  -3′ (forward) and 5′-T  T  G  T  T  G  C  C  C  A  G  G-
A  A  A  G  T  G  A  A  -3′ (reverse); MMP9, 5′-G  G  A  G  A  A  G  G  C  A  A  A  C  C  C  T  G  T  G  T  -3′ 
(forward) and 5′-A  G  G  C  T  G  T  A  C  C  C  T  T  G  G  T  C  T  G  G  -3′ (reverse); MMP14, 
5′-T  C  C  T  G  G  C  T  C  A  T  G  C  C  T  A  C  T  T  C  -3′ (forward) and 5′-G  G  T  G  T  C  A  A  A  G  T-
T  C  C  C  G  T  C  A  C  -3′ (reverse); CYR61, 5′-T  C  A  C  C  C  T  T  C  T  C  C  A  C  T  T  G  A  C  C  -3′ 
(forward) and 5′-A  G  G  G  T  C  T  G  C  C  T  T  C  T  G  A  C  T  G  A  -3′ (reverse); GAPDH, 
5′-T  G  G  C  C  A  A  G  G  T  C  A  T  C  C  A  T  G  A  C  -3′ (forward) and 5′-A  T  G  T  A  G  G  C  C  A  T  G-
A  G  G  T  C  C  A  C   -3′ (reverse).
Online supplemental material
Fig. S1 presents a control showing that LTBP1 cleavage occurs only 
with a form of BMP1 that is catalytically active and demonstrates that 
the LTBP1 N-terminal site is somewhat more efﬁ  ciently cleaved than the 
C-terminal site. Online supplemental material is available at http://www.
jcb.org/cgi/content/full/jcb.200606058/DC1.
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